We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UTHR or SDZNY: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR - Free Report) and Sandoz Group AG Sponsored ADR (SDZNY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, United Therapeutics is sporting a Zacks Rank of #2 (Buy), while Sandoz Group AG Sponsored ADR has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that UTHR likely has seen a stronger improvement to its earnings outlook than SDZNY has recently. But this is just one piece of the puzzle for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
UTHR currently has a forward P/E ratio of 19.43, while SDZNY has a forward P/E of 19.87. We also note that UTHR has a PEG ratio of 1.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. SDZNY currently has a PEG ratio of 1.74.
Another notable valuation metric for UTHR is its P/B ratio of 3.72. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, SDZNY has a P/B of 3.82.
These metrics, and several others, help UTHR earn a Value grade of B, while SDZNY has been given a Value grade of C.
UTHR stands above SDZNY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that UTHR is the superior value option right now.
View the Zacks #1 Rank List
Image: Bigstock
UTHR or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR - Free Report) and Sandoz Group AG Sponsored ADR (SDZNY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, United Therapeutics is sporting a Zacks Rank of #2 (Buy), while Sandoz Group AG Sponsored ADR has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that UTHR likely has seen a stronger improvement to its earnings outlook than SDZNY has recently. But this is just one piece of the puzzle for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
UTHR currently has a forward P/E ratio of 19.43, while SDZNY has a forward P/E of 19.87. We also note that UTHR has a PEG ratio of 1.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. SDZNY currently has a PEG ratio of 1.74.
Another notable valuation metric for UTHR is its P/B ratio of 3.72. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, SDZNY has a P/B of 3.82.
These metrics, and several others, help UTHR earn a Value grade of B, while SDZNY has been given a Value grade of C.
UTHR stands above SDZNY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that UTHR is the superior value option right now.